Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 749 across all filing types
Latest filing 2020-05-04 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) providing a clarification regarding the price movement of the company's shares. It references a regulatory query (NSE/CM/Surveillance/9437) and explains that the company has complied with disclosure regulations under SEBI (LODR) Regulations, 2015. The content focuses on explaining market-driven price changes and does not contain financial statements, audit information, or detailed report data. The document length is short (2950 characters) and is a regulatory communication rather than a financial report or announcement of a meeting or vote. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance communications that do not fit other specific categories.
2020-05-04 English
Updates
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 117 characters, indicating it is extremely short and does not contain any report content. There is no indication of any report, announcement, or filing type. Given the lack of content, the document cannot be classified as a report or announcement type and falls under the fallback category of Regulatory Filings (RNS).
2020-04-28 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges clarifying the movement in the company's share price. It references compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure obligations for listed companies. The content is a price movement clarification and does not contain financial data, report details, or any form of financial results or management discussion. The document length is short (1329 characters) and is clearly a regulatory disclosure or clarification rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other categories.
2020-04-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) providing an update on the company's response to a USFDA statement regarding Ranitidine. It discusses regulatory compliance, manufacturing process changes, and impact on revenues. The document is relatively short (4206 characters) and serves as an update or announcement rather than a detailed financial or operational report. It does not contain financial statements, detailed management discussion, or audit information. It is not a report publication announcement since it provides substantive update content. The content fits best under Regulatory Filings (RNS) as it is a regulatory update and compliance communication that does not fit other specific categories.
2020-04-09 English
Trading Window
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 68 characters) and contains no substantive content, financial data, or any identifiable report or announcement. It only includes placeholders and an omitted picture note. Therefore, it cannot be classified as any specific report type. Given the lack of content, the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2020-03-31 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015, concerning an advertisement published in newspapers about the intimation of a Board Meeting to consider an interim dividend and fixation of record date. It includes references to stock exchange filings and regulatory compliance but does not contain financial statements or detailed financial analysis. The document is essentially an announcement of an event (Board Meeting and dividend consideration) rather than a full financial report or detailed management discussion. It is also not a certification or insider dealing report. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.